Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents.
Many tumor types have p53 and/or RB mutations, and it is unclear what role the mutations of these tumor suppressor genes have on the efficacy of chemotherapeutic agents. The effect of p53 and RB inactivation on sensitivity to chemotherapeutic drugs was examined using a model system in which p53 or RB was inactivated in normal human foreskin fibroblasts (HFFs) by acute expression of human papillomavirus (HPV) 16E6 or 16E7. Cytotoxicity assays showed that HFFs expressing HPV 16E6 were 6- to 9-fold more sensitive to the DNA crosslinkers cisplatin and carboplatin and 7.8- to 11.5-fold more sensitive to the tubulin polymerizing agent paclitaxel than were LXSN-expressing cells. Analysis of mouse embryonal fibroblasts lacking p53 (p53-/-) compared with mouse embryonal fibroblasts homozygous (p53+/+) and heterozygous (p53+/-) for wild-type p53 confirmed the role of p53 in the enhanced sensitivity to cisplatin. Treatment with the alkylating agents melphalan and nitrogen mustard resulted in 3.8- to 7.3-fold greater sensitivity in HPV 16E6- or 16E7-expressing cells compared with LXSN-expressing cells. Enhanced sensitivity to cisplatin in cells lacking p53 function was explored by examination of its effects on cell cycle progression after exposure. When treated with cisplatin, HFFs expressing 16E6 showed delayed progression through S phase relative to HFFs expressing LXSN. The delay in S phase progression was coincident with the induction of p53 protein levels in LXSN-containing HFFs, suggesting a role for p53 in DNA repair of cisplatin-induced damage. These results indicate that the inactivation of p53 in the absence of other genetic alterations leads to enhanced sensitivity to multiple chemotherapeutic agents rather than to increased resistance.
Hawkins
D S
DS
Cancer Biology Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98104, USA.
Demers
G W
GW
Galloway
D A
DA
D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity*; D016590:Aphidicolin / Q000633:toxicity; D016190:Carboplatin / Q000633:toxicity; D002453:Cell Cycle / Q000187:drug effects; D002461:Cell Line, Transformed; D002470:Cell Survival / Q000187:drug effects; D002471:Cell Transformation, Neoplastic; D002478:Cells, Cultured; D002945:Cisplatin / Q000633:toxicity; D004622:Embryo, Mammalian; D005347:Fibroblasts; D016161:Genes, Retinoblastoma; D016158:Genes, p53; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D007231:Infant, Newborn; D007700:Kinetics; D008297:Male; D008466:Mechlorethamine / Q000633:toxicity; D008558:Melphalan / Q000633:toxicity; D051379:Mice; D009856:Oncogene Proteins, Viral / Q000096:biosynthesis; D017239:Paclitaxel / Q000633:toxicity; D027383:Papillomaviridae / Q000235:genetics / Q000378:metabolism; D050725:Papillomavirus E7 Proteins; D012097:Repressor Proteins; D012867:Skin / Q000166:cytology / Q000187:drug effects; D013997:Time Factors
D000970:Antineoplastic Agents; C068651:E6 protein, Human papillomavirus type 16; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; D012097:Repressor Proteins; C059731:oncogene protein E7, Human papillomavirus type 16; D016590:Aphidicolin; D008466:Mechlorethamine; D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin; D008558:Melphalan